Author name: DrugPatentWatch

Pharmaceutical value is not built exclusively in the laboratory. It is won and lost on the global chessboard of intellectual […]

KSR killed your obviousness defense. Amgen killed your functional claims. Here is the complete IP architecture for winning anyway, from

Part I — The Foundational Divide Why Biologic IP is a Different Discipline Entirely Before building any patent strategy, a

A brand-name drug loses 90% of its market share within 12 months of generic entry. That single data point explains

The IP landscape for small molecule drugs has never been harder to defend. R&D costs now exceed $2.23 billion per

Africa’s pharmaceutical market reached $27.65 billion in 2023 and is tracking toward $35 billion by 2032. South Africa alone is

The pharmaceutical R&D portfolio is the strategic core of the enterprise, a high-stakes arena where science, finance, and market dynamics

The patent system’s founding logic is straightforward: disclose an invention, receive a time-limited monopoly, then surrender it to the public.

Every blockbuster drug has two commercial lives. The first runs from approval to the loss of its composition-of-matter patent. The